FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration

Exudative Age-related Macular Degeneration Clinical Trial

— FUSION  

Official title:

FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01500915
• Other study ID #: FUSION-001-10-2010
• Status: Completed
• Phase: Phase 4
• First received: December 14, 2011
• Last updated: March 23, 2015
• Start date: November 2010
• Est. completion date: July 2012

Study information

• Verified date: March 2015
• Source: Institut de la Macula y la Retina
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety and efficacy of a combined fixed-interval and a pro re nata (PRN) regimens of ranibizumab (FUSION regimen) for the treatment of exudative age-related macular degeneration (AMD) in patients with good visual acuity (VA) at baseline. To establish whether similar efficacy to monthly regimens can be achieved with fewer injections, even in patients with good VA.

Description:

This is a prospective, open-label, consecutive interventional case series in treatment-naïve patients with exudative AMD. A loading phase of 2-3 injections is followed by a fixed-interval regimen of injections combined with a pro re nata regimen for 12 months. Endpoints include VA, presence of fluid at spectral domain optical coherent tomography (SD-OCT), adverse events and number of injections administered.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: July 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• subfoveal or juxtafoveal CNV owing to AMD, defined by fluorescein angiography (FA)

• presence on SD-OCT of subretinal or intraretinal fluid associated or not with macular edema

• Best corrected visual acuity (BCVA) in the study eye between 20/20 and 20/125, inclusive

• total area of the lesion (including blood, neovascularization and scar/atrophy) of =8 disc areas, of which at least 50% must be active choroidal neovascularization (CNV) (defined as the neovascular component of the lesion as defined by FA

• all angiographic subtypes [predominantly classic, minimally classic and occult] were eligible)

• clear ocular media and adequate pupillary dilatation to allow collection of fundus photographs and FA of a sufficient quality to be analyzed

• intraocular pressure of 21 mmHg or less

• and no previous treatment for AMD

Exclusion Criteria:

• presence of scarring or atrophy >75% of the total lesion size (patients with subfoveal scar or atrophy were excluded)

• subretinal haemorrhage >75% of the total lesion size; presence of serous retinal pigment epithelial detachments >5 disc areas

• presence of intraocular inflammation (= trace cell or flare), epiretinal membrane, macular hole or vitreous haemorrhage

• history of idiopathic or autoimmune-associated uveitis in either eye

• significant media opacities, including cataract, which might interfere with VA, assessment of toxicity or fundus photography in the study eye

• presence of other causes of CNV, including pathological myopia (spherical equivalent of -3 diopters or more, or axial length of 25 mm or more, or fundus findings suggestive of pathologic myopia), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture and multifocal choroiditis

• any retinal treatment (aside from antioxidants), including (but not limited to) intravitreal injections, photodynamic therapy with verteporfin, laser photocoagulation or surgery

• history of rhegmatogenous retinal detachment, pars plana vitrectomy or corneal transplant

• and previous radiation in the region of the study eye.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Exudative Age-related Macular Degeneration
• Macular Degeneration
• Wet Macular Degeneration

Intervention

Drug:
• Ranibizumab
0,5mg intravitreal ranibizumab

Locations

Country	Name	City	State
Spain	Institut de la Macula i de la Retina	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Institut de la Macula y la Retina	Centro Medico Teknon

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mean VA change	change in ETDRS (early treatment diabetic retinopathy study) letters from baseline to 12 month-visit	12 months	Yes
Secondary	Percentage of patients with gain of =5, >10 and =15 letters ETDRS	percentage of patients with gain of =5, >10 and =15 letters ETDRS at 12 months compared to baseline	12 months	Yes
Secondary	The percentage of patients losing <5, <15 and <30 ETDRS letters	percentage of patients with lost of <5, <15 and <30 ETDRS letters at 12 months compared to baseline	12 months	Yes
Secondary	The mean VA	mean VA at 6 and 12 months in ETDRS letters	6 and 12 months	Yes
Secondary	The median VA	median VA at 6 and 12 months in ETDRS letters	12 months	Yes
Secondary	The mean number of injections	the mean number of injections administered to patients from baseline to month 12 ( month 12 not included)	12 months	Yes